Skip to main content

ADVERTISEMENT

treatment

Conference Coverage
12/26/2019
Jessica Ailani, MD, answers our questions about new developments in therapeutics and technology, as well as overcoming the challenges of diagnosing and treating migraine.
Jessica Ailani, MD, answers our questions about new developments in therapeutics and technology, as well as overcoming the challenges of diagnosing and treating migraine.
Jessica Ailani, MD, answers our...
12/26/2019
Neurology
News
12/04/2019
Test your knowledge of the American Academy of Neurology/American Headache Society's Practice Guideline Update: Acute Treatment of Migraine in Children and Adolescents. See if you can answer this question correctly!
Test your knowledge of the American Academy of Neurology/American Headache Society's Practice Guideline Update: Acute Treatment of Migraine in Children and Adolescents. See if you can answer this question correctly!
Test your knowledge of the...
12/04/2019
Neurology
Review
12/01/2019
Ahad Ferdowsi Khosroshahi
Jafar Soleimani Rad
Raziyeh Kheirjou
Mohammad Reza Ranjkesh
Leila Roshangar
This review evaluates articles published on the Scopus, EMBASE, and PubMed databases that attempt to explain the pathophysiology, molecular components, and therapeutic approaches involved in the burn wound healing process.
This review evaluates articles published on the Scopus, EMBASE, and PubMed databases that attempt to explain the pathophysiology, molecular components, and therapeutic approaches involved in the burn wound healing process.
This review evaluates articles...
12/01/2019
Wounds
Poll
11/29/2019
Although no therapies are currently available for stroke rehabilitation, do you think it is possible that stem cell therapy will become more important among stroke survivors? Voice your opinion by taking our poll.
Although no therapies are currently available for stroke rehabilitation, do you think it is possible that stem cell therapy will become more important among stroke survivors? Voice your opinion by taking our poll.
Although no therapies are...
11/29/2019
Neurology
News
11/21/2019
Results of the Harmony III study highlight the long-term benefits of this FDA-approved therapy for narcolepsy. The drug also reduced common comorbidities, including cataplexy.
Results of the Harmony III study highlight the long-term benefits of this FDA-approved therapy for narcolepsy. The drug also reduced common comorbidities, including cataplexy.
Results of the Harmony III study...
11/21/2019
Neurology
Poll
10/17/2019
When relapsing-remitting multiple sclerosis worsens to secondary progressive multiple sclerosis, do you think disease-modifying therapies should be stopped? Let us know your opinion with our latest poll.
When relapsing-remitting multiple sclerosis worsens to secondary progressive multiple sclerosis, do you think disease-modifying therapies should be stopped? Let us know your opinion with our latest poll.
When relapsing-remitting...
10/17/2019
Neurology
Conference Coverage
09/05/2019
Edward L. Barnes, MD, MPH, from the University of North Carolina at Chapel Hill, answers our questions about the management of pouchitis in ulcerative colitis, a topic he will highlight during his session at the Advances in Inflammatory Bowel...
Edward L. Barnes, MD, MPH, from the University of North Carolina at Chapel Hill, answers our questions about the management of pouchitis in ulcerative colitis, a topic he will highlight during his session at the Advances in Inflammatory Bowel...
Edward L. Barnes, MD, MPH, from...
09/05/2019
Advances in Inflammatory Bowel Disease Network
Conference Coverage
08/14/2019
Scott D. Newsome, DO, from Johns Hopkins Medicine, answers our questions about new multiple sclerosis disease-modifying therapies, the challenges associated with prescribing these therapies, and more.
Scott D. Newsome, DO, from Johns Hopkins Medicine, answers our questions about new multiple sclerosis disease-modifying therapies, the challenges associated with prescribing these therapies, and more.
Scott D. Newsome, DO, from Johns...
08/14/2019
Neurology
Conference Coverage
07/12/2019
In addition to lowering the number of monthly migraine days, galcanezumab may also reduce the need for acute medication in patients with migraine. A new post-hoc analysis presented at the American Headache Society’s 61st Annual Scientific...
In addition to lowering the number of monthly migraine days, galcanezumab may also reduce the need for acute medication in patients with migraine. A new post-hoc analysis presented at the American Headache Society’s 61st Annual Scientific...
In addition to lowering the...
07/12/2019
Neurology
Conference Coverage
07/12/2019
In a phase 2b/3 study, a new orally administered CGRP receptor antagonist showed positive results in preventing migraines. Results were presented at the American Headache Society’s 61st Annual Scientific Meeting.
In a phase 2b/3 study, a new orally administered CGRP receptor antagonist showed positive results in preventing migraines. Results were presented at the American Headache Society’s 61st Annual Scientific Meeting.
In a phase 2b/3 study, a new...
07/12/2019
Neurology